The x10 System is available for CEOs of American F500s and Australian Blue Chips.

– x10 means multiply your business by ten!

– x10 Business Thinking is the simplest system for creating value across the enterprise.

– A business can become licensed to use the x10 Enterprise System for 12 months.

– The x10 System is simpler, faster and far less costly than any current system.

– The x10 System creates much more value than the current system. Ten times more!

The x10 Business Thinking system creates value through three business relationships:

In the x10 Business, all participants in each of the three collaborating relationships are cognitively engaged to use x10 Business Thinking to create value and multiply their business by ten.

What exactly is their business in the x10 enterprise?

Q What is the customer’s business?
A The business of the customer is to buy and tell (others by Word Of Mouth).

Q What is the employee’s business?
A The business of the employee is to make decisions every day to save a dollar or to make a dollar (working alone and in a local group).

Q What is the supervisor’s business?
A The business of the supervisor is to raise the quality and the quantity of decisions in the local group.

Q What is the leader’s business?
A The business of the leader is to provide problem-solving missions to local groups and to provide much better plans of execution.

Q What is the CEO’s business?
A The business of the CEO is to multiply the business by ten (by prioritising problems and opportunities for creating value; so allocating capital and leadership accountability).

Q What is the shareholder’s business?
A The business of the shareholder is to provide and grow capital (through investment, return on investment and re-investment).

In general, all daily business decisions made in F500 companies and Australian Blue Chips can be judged as either Good x10 Business Thinking or Bad x10 Business Thinking. The idea is to increase the first and reduce the second.

— CONTACT: Arrange a meeting with Michael and your CEO —

Dr Michael Hewitt-Gleeson is delighted to announce that the School of Thinking has recently appointed a distinguished panel of six senior science and business thinkers to review our major strategic initiatives for 2014.

They are Dr Graham Mitchell, Sir Gus Nossal, Professor David Penington, Dr John Stocker, Michael Taylor and Peter Turvey.

The first meeting was in January and these eminent thinkers will meet quarterly as a tertiary strategic review panel to add unique value to SOT global initiatives … …

Dr Graham Mitchell AO RDA BVSc FACVSc PhD FTSE FAA

Graham Mitchell is a veterinary graduate and University gold medallist of the University of Sydney. At The Walter and Eliza Hall Institute of Medical Research (WEHI) he made discoveries in immunology and obtained a PhD in 1969. After post-doctoral experience in California (Stanford), England (National Institute for Medical Research, Mill Hill) and Switzerland (Basel Institute for Immunology) he returned to Australia in 1973 and established a new program on the immunology of parasitism at WEHI. This program became a major component of the global effort to develop new tools for the control of parasitic diseases, and of the ‘biotechnology revolution’. Mitchell was instrumental in establishing a long term program on the disease schistosomiasis in the Philippines.

In 1990 Mitchell was appointed Director of the prestigious Royal Melbourne Zoological Gardens where he introduced a number of new initiatives in local and regional conservation.

In 1993 he returned to biomedical research as Director of Research in the R&D Division of CSL Limited, Australia’s largest developer, manufacturer and marketer of ethical human biologicals and veterinary products. He was responsible for identifying and assessing new opportunities for CSL, nurturing external research collaborations, and the research component of new product development including vaccines.

Mitchell is recognised as one of Australia’s leading biological scientists. His expertise extends over a wide range of science and technology. He has detailed knowledge of the academia-industry interface, has worked in many overseas countries and been involved with tropical disease programs of the World Health Organisation for many years. He is an author of more that 350 publications, has received numerous awards for scientific achievements and, in 1993, was appointed an Officer in the Order of Australia for services to science.

Mitchell has been an advisor on innovation to the Victorian, Commonwealth, Tasmanian and Northern Territory Governments. In another government role the Principals of Foursight, including Mitchell, jointly act as Chief Scientist for the Victorian Department of Environment and Primary Industries (DEPI). He is a non-executive director of Antisense Therapeutics Limited, Avipep Pty Ltd, Artisan Therapeutics Pty Ltd and WEHI. WIth Nossal, Penington and Stockerj he has been a Principal of Foursight, an advisory service in science, technology, innovation and commercialisation, since 1996 with new Principals, Mike Taylor and Peter Turvey, joining in 2012.

Sir Gustav Nossal AC CBE, FAA, FRS

Gustav Nossal was born in Bad Ischl, Austria, in 1931, and came to Australia with his family in 1939. He studied Medicine at the University of Sydney and, after residency at Royal Prince Alfred Hospital, took his Ph.D. at The Walter and Eliza Hall Institute of Medical Research in Melbourne. Apart from two years as Assistant Professor of Genetics at Stanford University, one year at the Pasteur Institute in Paris and one year as a Special Consultant to the World Health Organisation, all Nossal’s research career has been at the Hall Institute, of which he served as Director (1965-1996). Nossal was also Professor of Medical Biology at The University of Melbourne.

Nossal’s research is in fundamental immunology and he has written seven books and 550 scientific articles in this and related fields. Nossal has been President (1986-1989) of the 30,000 member world body of immunology, the International Union of Immunological Societies; President of the Australian Academy of Science (1994-1998); a member of the Prime Minister’s Science, Engineering and Innovation Council (1989-1998); and Chairman of the Victorian Health Promotion Foundation (1987-1996). He has been Chairman of the committee overseeing WHO’s Vaccines and Biologicals Programme (1993-2002) and Chairman of the Strategic Advisory Council of the Bill and Melinda Gates Children’s Vaccine Program (1998-2003).

Nossal was knighted in 1977, made a Companion of the Order of Australia in 1989 and appointed Australian of the Year in 2000. He has received numerous other honours from 11 countries. Amongst the most significant are Fellow of The Royal Society of London, Foreign Associate of the US National Academy of Sciences, Member of the Academie des Sciences France, the Robert Koch Gold Medal, the Albert Einstein World Award of Science, the Emil von Behring Prize, the Rabbi Shai Shacknai Prize and over 130 named lectureships in ten countries.

Nossal is also involved in charitable work as former Chairman of The Felton Bequests’ Committee; in the business community as a Principal of Foursight Associates Pty Ltd; in aboriginal affairs as former Deputy Chairman of the Council for Aboriginal Reconciliation; and in international advancement of Australia as former Chairman of The Global Foundation’s Advisory Council.

Since 2010, Nossal has been Chairman of the Gates Foundation’s Discovery Expert Group, charged with developing longer-term research strategies.  Given the Foundation’s emphasis on communicable diseases, he keeps in close touch with advances in this field.

Professor David Penington  AC, DM, MA(Oxon), FRCP, FRACP, FRCPA

Professor Penington was an undergraduate of the University of Melbourne (and Queens in 1950). He went to Oxford on a scholarship in 1950, graduating there in Medicine. He was a medical specialist, teacher and researcher in London. He returned to Melbourne in 1968 and was Professor of Medicine at the University of Melbourne from 1970 to ’87 and then Dean of the Faculty of Medicine for eight years.

Professor Penington was Vice-Chancellor of the University of Melbourne for eight years from 1988.

He was Chairman of the National AIDS Task Force (1983-87). From 1994 to 2001 he was President of Museum Victoria. He chaired the Victorian Premier’s Drug Advisory Council in 1995-96, a Committee on Drugs for Capital City Lord Mayors in 1997-1999 and the Drug Policy Expert Committee of the Victorian Government in 1999-2000. He has been a Fellow of Queens since the 1980s.

Professor Penington was Chairman of the Board of Cochlear Ltd from 1995 to 2002. He has been Chairman of the Bio21 Cluster from 2003 and Chairman of Bionic Vision Australia until 2013.

His autobiography “Making Waves: Medicine, Public Health, Universities and Beyond” published by Melbourne University Press July 2010.

Dr John Stocker AO MB BS BMedSc PhD FRACP FTSE

John Stocker has a distinguished career in pharmaceutical research and extensive experience in management of research and development and in its commercialisation. Stocker is a Director of Telstra and a Board member of Wine Victoria.

From 1976 to 1978 Stocker was a Member of the Basel Institute for Immunology in Switzerland. He joined the Swiss pharmaceutical company Hoffmann-LaRoche and Co in its Basel headquarters in 1979. His first position in the company’s Central Research Unit involved working on monoclonal antibodies and leading an international task force into the scientific and commercial opportunities offered by biotechnology-based vaccines. In 1986 he was appointed the company’s Director of Pharmaceutical Research and joined Hoffmann-LaRoche and Co’s International Research Board.

Stocker returned to Australia in 1987 to become the founding Managing Director of AMRAD Corporation Ltd, a company established to commercialise Australian biomedical discoveries. He was Chief Executive of CSIRO from 1990-1995 — the first Chief Executive to be appointed from outside the Organisation. He later returned to CSIRO as Chairman from 2007-2010. He was also Chairman of Sigma Pharmaceuticals from 2005 — 2010. John Stocker was the Australian Government’s Chief Scientist and from December 1996 to April 1999 served as Chairman of the Australian Science and Technology Council (ASTEC). He was a foundation member of the Prime Minister’s Science, Engineering and Innovation Council and has been a member of the Australian Research Council and of the Australia China Council. He was Chairman of the Grape and Wine Research and Development Corporation from 1996-2003 and a member of the Board of The Walter and Eliza Hall Institute for Medical Research from 2000 to 2006. He served as a director of the UK company, Cambridge Antibody Technology Group plc from 1996 to 2006. The Australian newspaper named him ‘Australian of the Year’ in February 1992. He was appointed an Officer in the Order of Australia in June 1999 and was awarded the Centenary Medal in 2003.

He is currently a director of Wine Victoria and a non-executive member of the Executive Management Committee of the Australian Department of Agriculture Fisheries and Forestry.

He is married and has two daughters. He plays tennis and has interests in viticulture and Australian native trees.

Michael John Taylor  AO BAgSC DipAgEcon FTSE

Mike Taylor is currently a Principal of Foursight Associates, the part time Chair of the Geoffrey Gardiner Dairy Foundation, and Director of the Public Transport Development Authority, Country Fire Authority, Bush Fire Cooperative Research Centre, Director Public Transport Development Authority, Crawford Fund for International Agricultural Research and Melbourne University – Melbourne Business School.

Mike was formerly the Secretary to Australia’s Department of Infrastructure, Transport and Regional Services — Australia (2004-09), and Secretary, Department of Agriculture, Fisheries & Forestry — Australia (2000-04).  Prior to that, he was responsible for the leadership and management of three Departments for the Government of Victoria (1992-2000) (Agriculture, Energy and Minerals, and Natural Resources and Environment), and was Chairman of Murray Darling Basin Authority (2009-11).

As a result he has been extensively involved in preparing and negotiating International, Commonwealth, State and industry agreements and legislation, and in advising the Governments and Commonwealth / State Ministerial Councils on a wide range of transport, security, regional development, water, energy, minerals, agricultural, food, forestry, fisheries, environmental and sustainable natural resource management issues.

Mike’s experience in management, marketing, economic policy and planning has resulted in appointments to numerous boards of external organisations. He has also participated in and chaired a wide range of international negotiations, meetings, delegations, projects, policy and trade development work in Asia, North America and Europe. Mr Taylor speaks regularly at a wide range of industry and management conferences and forums.

Peter R Turvey BA/LLB, MAICD

Peter Turvey is the former Executive Vice President Licensing and Company Secretary of global specialty biopharmaceutical company CSL Limited having retired in 2011. He is currently a director of the industry organisation AusBiotech Limited and a non-Executive Director of Starpharma Holdings Limited.

After completing an Arts/Law degree at the Australian National University, he joined Biotechnology Australia, then Australia’s largest biotechnology company, as Manager of Intellectual Property and Company Secretary.  He joined CSL in 1992 as its first in-house Corporate Counsel and was appointed Company Secretary in 1998.  He played a key role in the transformation of CSL from a government owned enterprise, through ASX listing in 1994, to a global plasma and biopharmaceutical company.

He also had responsibility for the protection and licensing of CSL’s intellectual property and for risk management within CSL, which included management of the internal audit function, reporting to the Audit & Risk Management Committee of the Board as well as being the Chairman of the Corporate Risk Management Committee.

Among the many licensing deals he was involved with, the most significant included the Gardasil license to Merck & Co., the licensing of the Iscomatrix® adjuvant platform technology to the world’s leading vaccine manufacturers, and establishment of the P.gingivalis vaccine technology collaboration between the CRC for Oral Health and Sanofi-Pasteur.

Peter is a non-executive director of Starpharma Holdings Limited and Allied Healthcare Group Limited, both companies listed on the Australian Securities Exchange, non-executive director of Agriculture Victoria Services Pty Ltd and AusBiotech Limited, the Industry Organisation for the Australian Life Science Sector.

These advisors are all Principals of Foursight Associates.

School of Thinking teaches X10 THINKING by helping you to understand some interesting and useful facts about basic cognitive neuroscience and the plasticity of your brain so you can upgrade your own thinking software … new apps for your brain.

Scientists call this “thinking about thinking” – metacognition. The School of Thinking (SOT) Motto in Latin is:

NEMO NASCITUR SAPIENS ARTIFEX.

In English this motto is: ‘No-one is ever born a skilled thinker!’

— Click through to the first School of Thinking lesson …

Where is the proof in pseudoscience?

The word “pseudoscience” is used to describe something that is portrayed as scientific but fails to meet scientific criteria.

The Conversation

By Peter Ellerton

This misrepresentation occurs because actual science has creditability (which is to say it works), and pseudoscience attempts to ride on the back of this credibility without subjecting itself to the hard intellectual scrutiny that real science demands.

A good example of pseudoscience is homoeopathy, which presents the façade of a science-based medical practice but fails to adhere to scientific methodology.

Other things typically branded pseudoscience include astrology, young-Earth creationism, iridology, neuro-linguistic programming and water divining, to name but a few.

What’s the difference?

Key distinctions between science and pseudoscience are often lost in discussion, and sometimes this makes the public acceptance of scientific findings harder than it should be.

For example, those who think the plural of anecdote is data may not appreciate why this is not scientific (indeed, it can have a proper role to play as a signpost for research).

Other misconceptions about science include what the definition of a theory is, what it means to prove something, how statistics should be used and the nature of evidence and falsification.

Because of these misconceptions, and the confusion they cause, it is sometimes useful to discuss science and pseudoscience in a way that focuses less on operational details and more on the broader functions of science.

What is knowledge?

Testing the knowledge.
The first and highest level at which science can be distinguished from pseudoscience involves how an area of study grows in knowledge and utility.

 

 

 

 

 

 

 

 

The philosopher John Dewey in his Theory of Inquiry said that we understand knowledge as that which is “so settled that it is available as a resource in further inquiry”.

This is an excellent description of how we come to “know” something in science. It shows how existing knowledge can be used to form new hypotheses, develop new theories and hence create new knowledge.

It is characteristic of science that our knowledge, so expressed, has grown enormously over the last few centuries, guided by the reality check of experimentation.

In short, the new knowledge works and is useful in finding more knowledge that also works.

No progress made

It’s all in the stars.

Contrast this with homeopathy, a field that has generated no discernible growth in knowledge or practice. While the use of modern scientific language may make it sound more impressive, there is no corresponding increase in knowledge linked to effectiveness. The field has flat-lined.

 

 

 

At this level of understanding, science produces growth, pseudoscience does not.

To understand this lack of growth we move to a lower, more detailed level, in which we are concerned with one of the primary goals of science: to provide causal explanations of phenomena.

Causal explanations

Causal explanations are those in which we understand the connection between two or more events, where we can outline a theoretical pathway whereby one could influence the others.

This theoretical pathway can then be tested via the predictions it makes about the world, and stands or falls on the results. Classic examples of successful causal explanations in science include our explanation of the seasons, and of the genetic basis of some diseases.

While it’s true that homoeopathy supporters try very hard to provide causal explanations, such explanations are not linked to more effective practice, do not provide new knowledge or utility, and so do not lead to growth.

In the same way, supporters of neuro-linguistic programing claim a causal connection between certain neurological processes and learned behaviour, but fail to deliver, and astrologists offer no coherent attempt to provide an explanation for their purported predictive powers.

 

 

 

 

What is neuro-linguistic programing?
 

 

 

The lack of testable causal explanations (or models, if you will) that characterises pseudoscience gives us a second level of discrimination: science provides casual explanations that lead to growth but pseudoscience does not.

Operational aspects of science

The third level of discrimination is where most of the action between science and pseudoscience actually takes place, over what I earlier called the operational details of science. Getting these details right helps deliver useful causal explanations.

This is where battles are fought over what constitutes evidence, how to properly use statistics, instances of cognitive biases, the use of proper methodologies and so on.

It is where homeopathy relies on confirmation bias, where the anti-vaccine lobby is energised by anecdotes, and where deniers of climate science selectively highlight agreeable data.

This level is also where the waters are muddiest in terms of understanding science for much of the population, as seen in comments on social media posts, letters to the editor, talkback, television, media articles and political posturing.

The knowledge is out there

It is important to address these basic operational understandings, but we must also highlight, in both science education and science communication, the causal explanations science provides about the world and the link between these explanations and growth in knowledge and utility.

This understanding gives us better tools to recognise pseudoscience in general, and also helps combat anti-science movements (such as young-earth creationism) that often masquerade as science in their attempt to play in the same rational arena.

A vigorous, articulate and targeted offence against pseudoscience is essential to the project of human progress through science, which, as Einstein reminds us, is “the most precious thing we have”.

The Conversation

– This article was originally published at The Conversation.
– Read the original article.